SITC 2022 | Developing novel T-cell therapeutics for patients with melanoma who do not respond to ICI’s

Cristina Puig Saus, PhD, University of California, Los Angeles, talks on the development of novel T-cell therapies for patients with melanoma who do not respond to immune checkpoint inhibitors (ICI’s). The T-cell receptor (TCR) of isolated neoepitope-specific T-cells of patients who respond to ICI’s were cloned and expanded in healthy donors to assess and validate the reactivity against the melanoma cell lines. Now the tumor reactivity of the neoepitope-specific T-cells have been validated, the next steps in this line of research may involve the collection of white blood cells of patients who do not respond to ICI’s to modify them to express the tumor reactive neoepitope-specific T-cells, to then expand and reinfuse back into the non-responders. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.